Gene mutation

Blood cells
#FDA #Gene mutation #Genetic diseases #Rare disease #Takeda

First therapy for very rare blood clotting disorder gets US greenlight

Takeda’s Adzynma has become the first recombinant protein product approved in the US for prophylactic or on-demand enzyme replacement therapy (ERT) for congenital thrombotic thrombocytopenic purpura (cTTP). A very rare, inherited blood clotting disorder, cTTP is caused by a disease-causing mutation in the ADAMTS13 gene, which is responsible for making… Read More

#Editor's Choice #News #Regulatory

Prostate cancer cells
#FDA #Gene mutation #Janssen #Oncology #Phase III trial #Prostate cancer

FDA approves dual action tablet for BRCA-positive prostate cancer

Janssen’s Akeega (niraparib and abiraterone acetate) is now available in the US for adult patients with deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC) following FDA approval. It is the first dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, to be approved in… Read More

#News #Regulatory

Breast cancer cell
#Cancer research #Gene mutation #Oncology #PARP inhibitors #The Institute of Cancer Research

PARP inhibitor use could be extended to more cancer patients

New findings suggest PARP inhibitor drugs, used to treat cancer patients who have an altered BRCA1 or BRCA2 gene, may also be effective for patients which have changes in the SF3B1 gene. If further research supports these findings, there is the potential that existing PARP inhibitor… Read More

#Cancer Research #Editor's Choice #News

Genetics
#Cancer research #Gene mutation #Genetics / genomics #Oncology #Precision medicine

3D genomics and targeted cancer therapies

Listen to this article on the DDW Podcast: Anthony Schmitt, PhD, Senior Vice President, Science at Arima Genomics, discusses the applications of 3D genomics in cancer research. Efforts to fulfil the promise of precision medicine, including the use of targeted cancer therapies, necessitate that patients be treated based on the specific genetic… Read More

#Cancer Research #Exclusive Content

Gene sequence
#AACR 2023 #Cancer research #Gene mutation #Genetics / genomics #Oncology #Whole genome sequencing

Exome sequencing proves current cancer risk testing is inadequate

Exome sequencing correctly identified individuals with cancer predisposition syndromes who would have been missed by current screening guidelines, according to results from the Tapestry clinical trial. Data presented at the AACR Annual Meeting 2023 showed that among individuals who consented to whole-exome sequencing and were identified… Read More

#Cancer Research #News #Trending News

Male patient with doctor
#Cancer research #CHMP #European Medicines Agency #Gene mutation #Oncology #Phase III trial #Prostate cancer

Prostate cancer combination therapy reduces risk of death

The combination therapy of niraparib and abiraterone acetate (AA) could become the first dual action tablet (DAT) available in the European Union for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations.  Janssen’s Akeega has been recommended for marketing authorisation when given with prednisone (P) or prednisolone by the Committee for… Read More

#News #Regulatory

Cancer cells
#Breast cancer #Cancer research #FDA #Gene mutation #Genetics / genomics #Menarini #Oncology #Stemline Therapeutics

FDA-approved therapy targets ESR1 mutations in breast cancer

The first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer has been approved in the US.  The Food and Drug Administration (FDA) has approved Orserdu (elacestrant) for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced… Read More

#News #Regulatory

Mammography
#Breast cancer #Cancer research #European Commission #Gene mutation #Genetics / genomes #HER2 #Oncology

Drug approved for breast cancer with low levels of HER2 expression

Enhertu has been approved in the EU as the first HER2 directed therapy for patients with HER2 low metastatic breast cancer.  The drug is approved as monotherapy for adult patients who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six… Read More

#Cancer Research #Editor's Choice #News

#DNA #Gene mutation #Gene sequencing #Paediatrics #Rare disease

Researchers investigate genetic variants of paediatric diseases 

PacBio, developer of sequencing solutions, has announced its HiFi sequencing technology will be used in a pilot project for the Children’s Rare Disease Cohorts Initiative (CRDC) at Boston Children’s Hospital.   Boston Children’s Hospital researchers will use HiFi whole-genome sequencing (HiFi WGS) for the purpose of investigating genetic… Read More

#News

Next generation sequencing
#Gene expression #Gene mutation #Next generation sequencing #RNA sequencing #Single-cell RNA sequencing

Is single-cell gene expression the next trend in next generation sequencing? 

Listen to this article on the DDW podcast: By Dr Dina Finan, PhD, Product Manager at 10x Genomics and Dr Nick Downey, PhD, NGS Collaborations Lead at Integrated DNA Technologies.  RNA sequencing has become a widely used tool that can explore the transcriptome in a seemingly endless number of applications. While bulk sequencing—or… Read More

#Editor's Choice #Exclusive Content

#Collaboration #Drug development #Drug discovery #Gene mutation #Research #Schizophrenia

This week in drug discovery (13-17 September) 

News round-up by DDW’s Megan Thomas for 13-17 September  The news in the drug discovery industry this week has demonstrated the potential that remains untapped for a number of industries at large as well as taking early steps towards future cures and treatments. DDW’s Megan Thomas has… Read More

#News #Trending News

#Biomarkers #Collaboration #Gene mutation #Gene therapy

Illumina and Merck partner to identify cancer mutations 

Illumina and Merck have partnered to develop and commercialise tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD).   Patients whose tumours are HRD-positive may be eligible for targeted treatment by a class of precision medicines called PARP inhibitors. The HRD tests will leverage Illumina’s TruSight Oncology 500 (TSO… Read More

#News

#Cancer #Gene mutation #KRAS

Lumykras receives MHRA approval in the UK for lung cancer patients  

Amgen UK’s first-in-class medicine sotorasib (a targeted KRAS G12C inhibitor formerly named AMG 510) has become the first new cancer therapy to receive Conditional Marketing Authorisation for use1 across England, Scotland and Wales by the Medicines and Healthcare products Regulatory Agency (MHRA) under Project Orbis. This authorisation follows a review of sotorasib’s role in treating patients with… Read More

#News #Trending News

#Clinical trials #Gene editing #Gene mutation #Gene therapy #Genetics / genomics #Research

Exploring gene-based medicine’s true potential

Listen to this article on the DDW Podcast: By Christopher Doyle, PhD, Director, IBC Services at WCG The Covid-19 pandemic spawned a flurry of research that culminated in the development of several vaccines that express viral proteins from recombinant or synthetic genetic material. The success of these new vaccines thrust the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News